SECURITIES AND EXCHANGE COMMISSION
WASHINGTON D.C. 20549
------------
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): August 17, 2004
Eyetech Pharmaceuticals, Inc.
- --------------------------------------------------------------------------------
(Exact Name of Registrant as Specified in Charter)
Delaware 000-50516 13-4104684
- ---------------------------- -------------------- ----------------------
(State or Other Jurisdiction (Commission (I.R.S. Employer
of Incorporation) File Numbers) Identification No.)
3 Times Square, 12th Floor
New York, NY 10036
- ---------------------------------------- ----------------
(Address of Principal Executive Offices) (Zip Code)
Registrant's telephone number, including area code: (212) 824-3100
- --------------------------------------------------------------------------------
(Former name or former address, if changed since last report)
Item 9. Regulation FD Disclosure
On August 17, 2004, Eyetech Pharmaceuticals, Inc. and Pfizer Inc
announced the acceptance by the U.S. Food and Drug Administration of their
complete new drug application for the use of Macugen(TM) (pegaptanib sodium
injection) in the treatment of neovascular age-related macular degeneration. The
full text of the press release issued in connection with the announcement is
furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The furnishing of the attached press release is not an admission as to
the materiality of any of the information set forth herein or in such press
release.
The information in this Item 9 of Form 8-K (including Exhibit 99.1)
shall not be deemed "filed" for purposes of Section 18 of the Securities
Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the
liabilities of that section, nor shall it be deemed incorporated by reference in
any filing under the Securities Act of 1933 or the Exchange Act, except as
expressly set forth by specific reference in such a filing.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Date: August 18, 2004 EYETECH PHARMACEUTICALS, INC.
By: /s/ Glenn P. Sblendorio
---------------------------
Name: Glenn P. Sblendorio
Title: Senior Vice President, Finance and
Chief Financial Officer
EXHIBIT INDEX
Exhibit No. Description
- ----------- -----------
99.1 Press release dated August 17, 2004 announcing the
acceptance by the U.S. Food and Drug Administration of
Eyetech and Pfizer Inc's complete new drug application for
the use of Macugen(TM) (pegaptanib sodium injection) in the
treatment of neovascular age-related macular degeneration.